Form 4 for VTGN Vistagen Therapeutics, Inc.
Accepted 2022-01-03 00:00:00 ET · period of report 2021-12-31 · accession 0001415889-22-000046 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-01-03 | 2021-12-31 | VTGN | Smith Mark Alan | Chief MEDICAL Off | A - Grant | $1.66 | +2,655 | 14.9K | +22% | +$4,407 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-31 | A | A | 2,655 | $1.66 | 14,915 | D | — | — | (F1) Shares purchased under the VistaGen Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c) |